This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of 3 doses of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
Natriuresis
Urinary sodium excretion
Time frame: 24 hours
Body weight
Changes in body weight
Time frame: 7 days
NT-proBNP
Changes in NT-proBNP
Time frame: 7 days
Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)
Changes in KCCQ-TSS - The score ranges from 0 to 100 with higher score indicating a better health status
Time frame: 28 days
Left Atrial Volume index (LAVi)
Changes in LAVi - LAV-i is an index of cardiac function measured by echocardiogram
Time frame: 2 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States
Wayne State University - Detroit Receiving Hospital
Detroit, Michigan, United States
Wayne State University - Sinai Grace Hospital
Detroit, Michigan, United States
Cone Health Moses Cone Hospital
Greensboro, North Carolina, United States
NC Heart and Vascular Research, LLC
Raleigh, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
South Oklahoma Heart Research, LLC
Oklahoma City, Oklahoma, United States
Fakultní nemocnice Brno
Brno, Czechia
Sdružené zdravotnické zařízení Krnov
Krnov, Czechia
Fakultní nemocnice Ostrava
Ostrava, Czechia
...and 45 more locations